Two Monoclonal Antibody Drugs Are Rendered Useless by Omicron
By Radiant Health EditorsPublished: January 30, 2022
The FDA has decided to restrict the use of two types of monoclonal antibody treatments. The drugs were previously made available in the U.S. because they were effective against other variants of Covid-19, but research shows that they do little to work against the Omicron variant. At this point, 99% of all positive cases in the country are due to the Omicron variant, so the drugs serve no purpose. The only monoclonal antibody treatment that has been approved for use against Omicron, sotrovimab, is available in very few places in the country.
Like what you're reading? Sign up for our free newsletter and never miss a post! Plus get a FREE digital version of our Issue No.10 with sign up.
- Coconut Cauliflower Rice With Jerk Chicken - November 29, 2024
- Protein Cottage Cheese Pancakes - November 27, 2024
- How To Reduce Screen Time On Phone: 5 Helpful Strategies To Help You Stay Connected With The Real World - October 30, 2024
- 11 Wellness Gift Ideas: Perfect Presents for Her that Nurture Body, Mind, and Soul - October 13, 2024
- 11 Best Indoor Air Purifying Plants: Nature’s Air Filters for Your Home - September 27, 2024
- 11 Best Health and Wellness Books to Read in 2025 - July 4, 2024
- Some Americans Will Have Medical Debt Wiped From Credit - July 9, 2022
- Natural Gas Used to Heat Homes Contains Some Harmful Chemicals - July 9, 2022
- Uterine Cancer Claims Many Black Lives - July 9, 2022
- Babies and Toddlers Get COVID-19 Shots - June 27, 2022